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Patients undergoing hematopoietic cell transplantation (HCT) can have complications that require manage-
ment in the intensive care unit (ICU). We conducted a retrospective study of patients undergoing HCT be-
tween 2007 and 2011 with admission to the ICU. We analyzed 97 patients, with an average age of 37 (range,
15 to 68). The main indications for HCT were hematologic malignancies (84%, n ¼ 82). Ninety percent (n ¼ 87)
received myeloablative conditioning. Thirty-one percent were admitted (autologous transplant recipients
15%, allogeneic transplant recipients 34%, and umbilical cord blood [UCB] transplant recipients 48%) with an
average length of stay of 19 days (range, 1 to 73 days). The average time between transplantation and transfer
was 15 days. The main causes of admission were acute respiratory failure (63%) and septic shock (20%). ICU
mortality was 20% for autologous transplantations and 64% for allogeneic transplantations (adult donor and
UCB combined). On average, patients died 108 days after the transplantation (range, 4 to 320 days). One-year
overall survival, comparing patients entering the ICU with those never admitted, was 16% versus 82%
(P < .0001) for allogeneic transplantations (adult donor and UCB combined) and 80% versus 89% (P ¼ not
signiﬁcant) for autologous transplantations. Acute graft-versus-host disease was signiﬁcantly associated with
death in ICU after UCB HCT. ICU support is satisfactory in about one half of patients admitted, characterized by
a short and medium term prognosis not as unfavorable as has been previously reported.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION HCT patients who require ICU care during transplantation
Autologous and allogeneic hematopoietic cell trans-
plantation (HCT) is a potentially curative treatment for many
hematologic malignancies and hereditary disorders. How-
ever, this therapy is associated with signiﬁcant morbidity
and mortality for the recipient, and between 11% and 40% of
patients require admission to the intensive care unit (ICU),
according to various reports [1].
Initial series suggested an ominous prognosis over the
short and medium term for transplantation patients after a
stay in the ICU, especially in those who required ventilation
support [2-6]. Overall survival rates at 6 months of less than
5% [7] were reported, giving rise to restrictions and limita-
tions to ICU access or measures of support for these patients
[8-12].
Recently, several studies have been published that sug-
gest that the prognosis of patients with hematological ma-
lignancies in the ICU has improved during the last decade
[13,14], even in recipients of HCT [15-17].
There are no reports in Chile in this regard, and there is
usually a reluctance to admit hematologic or HCT patients to
local ICU units, considering older international reports
showing poor survival of this population and limitations of
resources, especially in public hospitals. In this study, we
show for the ﬁrst time in our country and institution thatedgments on page 179.
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PATIENTS AND METHODS
This analysis includes all adult HCT patients in the Health Network at the
Universidad Católica de Santiago, between January 2007 and December
2011, who required admission to the ICU for any complication resulting from
their transplantation during the ﬁrst year of follow-up.
The information was obtained from the database of the HCT unit at the
Health Network of the Universidad Católica. Demographic data were
extracted and related to the hematologic disease database. We also extrac-
ted the conditioning regime used, type of transplantation performed
(autologous, allogeneic [related or unrelated], and umbilical cord blood
[UCB]), admission to ICU, time from HCT to admission to the ICU
and duration of stay, and mortality in the ICU and during the ﬁrst year of
follow-up.
A descriptive analysis of the data obtained follows. Variables are re-
ported as numbers and percentages. Survival curves were obtained using
the Kaplan-Meier method and were compared with the log-rank test [18].
The statistical analysis was performed using SPSS software version 21 (IBM
Corp., Armonk, NY).
RESULTS
Patients Characteristics
During the study period, 97 HCT were performed on pa-
tients with an average age of 36.9 years (range, 15 to 68). The
main indications for HCT were hematologic malignancies
(81%, n ¼ 79), with acute leukemias in 50% of cases (n ¼ 48).
The main conditioning regimens were myeloablative, which
included drugs such as cyclophosphamide, carmustine,
melphalan, etoposide, busulfan, and total body irradiation.
Demographic data are shown in Table 1.
ICU Admission
Thirty-one percent of patients (n ¼ 30) required admis-
sion to the ICU during the ﬁrst year after transplantation; the
average age was 37.4 years (range, 15 to 58). Speciﬁcally,
Table 1
Patients Demographics
Characteristic All Autologous Allogeneic UCB
No. of patients 97 33 41 23
Age, mean (range), yr 37 (15-68) 48 (21-68) 33 (17-56) 27 (15-55)
Diagnosis (n, %)
ALL 28 (29%) - 17 (42%) 11 (48%)
AML 20 (21%) 1 (3%) 13 (32%) 6 (26%)
NHL 13 (13%) 10 (30%) 1 (2%) 2 (9%)
HL 5 (5%) 4 (12%) 1 (2%) -
MM 13 (13%) 13 (39%) - -
Others 18 (19%) 5 (16%) 9 (22%) 4 (17%)
Conditioning (n, %)
MA 87 (90%) 30 (91%) 34 (83%) 23 (100%)
RIC 10 (10%) 3 (9%) 7 (17%) -
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; MM, multiple
myeloma; MA, myeloablative conditioning; RIC, reduced-intensity
conditioning.
Figure 1. Number of patients admitted in the ICU versus patients who survive
ICU. Overall and according to different transplantation types.
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underwent autologous HCT, 34% (n ¼ 14) of patients who
underwent allogeneic HCT, and 48% (n ¼ 11) of patients who
underwent UCB HCT. The average length of stay in the ICU
was 19 days (range, 1 to 73 days): 13 days for recipients of
autologous HCT, 16 days for recipients of allogeneic HCT, and
22 days for recipients of UCB HCT.
The main reasons for admission to the ICU were acute
respiratory failure (63%; n ¼ 19), septic shock (20%; n ¼ 6),
and neurological complications (13%; n ¼ 4), with a similar
distribution between the various types of transplantations.
One patient was admitted for acute myocardial infarction. It
was not always possible to establish the exact cause of res-
piratory failure, as this group includes viral, bacterial, and
fungal infections and pulmonary hemorrhage.
The infections were documented in 24 patients, with the
following distribution: bacterial etiology in 13 patients, viral
in 4 patients (3 due to a reactivation of cytomegalovirus), and
fungal infection in 7 patients (6 patients by invasive
aspergillosis).
ICU Mortality
The proportion of patients admitted to the ICU and dying
there was 20% (1 of 5) for autologous HCT patients, 64% (9 of
14) for allogeneic HCT patients, and 64% (7 of 11) of UCB HCT
patients (Figure 1). On average, patients died 108 days
(range, 4 to 320 days) after their transplantation (10, 131, and
119 days for autologous, allogeneic, and UCB HCT, respec-
tively). ICU admissions due to respiratory failure were asso-
ciated with higher mortality rates than nonrespiratory
indications in allogeneic and UCB HCT. Globally, 63% (12 of
19) of patients died when respiratory failure was the reason
for ICU admission versus 45% (5 of 11) of patients when
nonrespiratory conditions were the indications for ICU
admission. Overall, the ICU admission rate was similar be-
tween nonengrafted (47%) and engrafted patients (53%).
The main causes of death within the ICU were respiratory
complications (47%; 9 of 19) and refractory septic shock (21%;
4 of 19), whereas the remainder had various etiologies.
Survival after ICU Discharge
Comparing patients who were admitted to the ICU
(n ¼ 30) with those not requiring admission to the ICU
(n ¼ 67), overall survival (OS) was 26% (8 of 30) and 85% (57
of 67), respectively (P ¼ .0001), 1 year after HCT (Figure 2A).
Subgroup analysis showed no differences in OS in patientsundergoing autologous HCT who required ICU versus those
not requiring ICU, 80% (4 of 5) versus 89% (25 of 28) (P ¼ not
signiﬁcant). However, allogeneic (adult and UCB HCT pa-
tients) recipients had signiﬁcant lower OS when requiring
ICU versus those not requiring ICU, 16% (4 of 25) versus 82%
(32 of 39) (P < .0001) (Figure 2B,C).Graft-versus-Host Disease and Risk of Death in the ICU
In the allogeneic adult graft group, 36% of patients
developed acute graft-versus-host disease (GVHD) (5 of 14
patients at risk): 80% moderate (n ¼ 4; skin) and 20% severe
(n ¼ 1; liver). On average, these patients died 174 days after
transplantation (range, 50 to 280). Thirty percent of patients
developed localized skin chronic GVHD (2 of 7 patients at
risk). In the UCB group, 45% of patients developed acute
GVHD (5 of 11 patients at risk): 80% moderate (n ¼ 4; liver,
skin, and intestine) and 20% severe (n ¼ 1; skin and intestine
in 1 patient). All these patients died, on average, 195 days
after transplantation (range, 60 to 150). One of 5 patients at
risk (20%) developed intestinal chronic GVHD.
When comparing ICU deaths in UCB HCT in patients with
or without acute GVHD, 50% (4 of 8) of the patients had acute
GVHD versus only 13% (1 of 8) of patients without acute
GVHD. In adult allogeneic grafts, 36% (5 of 14) of the patients
who died had acute GVHD versus 43% (6 of 14) of the patients
who did not have acute GVHD.DISCUSSION
This study covers a 5-year period and is the ﬁrst report
from a Chilean university transplantation center on patients
who underwent HCT and subsequently required admission
to the ICU, evaluating the short- and medium-term results.
Various studies between 1990 and 2000 described a poor
prognosis for HCT patients in the ICU, particularly for those
requiring invasive mechanical ventilation (IMV), even cast-
ing doubt on the actual beneﬁt of intensive support for this
subgroup of patients [8-12].
Currently, there is a large variation in the reported OS
rates of patients with hematologic malignancies in the ICU,
although the results of the studies of better quality and with
a greater number of patients describe that approximately
40% of patients survive the hospital stay and that 20% of them
are still alive at 6 months. For those patients who underwent
some form of HCT, the data are less robust and reported OS in
the medium- and long-term is 29% and 15%, respectively
[19]. These differences in the results can be explained, at
least in part, by the different types of HCT included in the
studies, the variation in admission criteria to the ICU and for
Figure 2. One-year OS from HCT, comparing ICU admitted patients versus
patients not admitted in the ICU. (A) Shows all patients, (B) shows autologous
recipients, and (C) shows allogeneic (adult donors and UCB) recipients.
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therapeutic decisions taken by medical teams.
Despite these differences, recent studies suggest a better
prognosis for these patients, attributed to various factors,
including better support in intensive care units, integrated
management by highly specialized multidisciplinary teams,
development of new diagnostic and therapeutic strategies,
improvements in the selection of patients for HCT, reduc-
tion in the intensity of regimen constraints, use of target
drugs associated with lower organic toxicity, use of pe-
ripheral blood as a source of stem cells, antimicrobial pro-
phylaxis in the period before and after HCT, evolution in themanagement of GVHD, and the use of colony-stimulating
factors [20].
Our study describes an OS rate after 1 year in all patients
receiving HCT of 68%. In patients requiring admission to the
ICU, 57% died in the unit and 1 year later, 26.7% were still
alive, similar to rates reported in contemporary international
series [15,21-25].
As in most of the series, in our review the main cause of
admission and death in the ICU was respiratory failure,
which also was associated with a higher death risk when
compared with nonrespiratory indications for ICU admission
[15,22,25-27]. Although there is no speciﬁc factor to predict
mortality in HCT patients, various reports have attempted to
assess predictors. IMV and multiorgan failure have been
classically described as relevant [15,21-23,25,28,29].
Although acute GVHD only affects a small number of
patients, it is interesting to see that in UCB transplantations,
there was almost 4 times the risk of death in the ICU when a
patient had acute GVHD compared with not having acute
GVHD (50% versus 13%, respectively). In contrast, that risk of
death was similar in adult allogeneic grafts when comparing
the patients who died in the ICU who did or did not present
with acute GVHD (36% versus 43%, respectively). One
explanation for this is that UCB HCT had more moderate and
severe involvement of the intestine and liver compared with
only 1 case of severe liver acute GVHD in an adult allogeneic
graft recipient.
The inherent limitations to our work are the retrospective
nature of our study, the small number of patients included,
and a single center analysis. However, this is the ﬁrst study at
a national level that evaluates this problem and raises the
question, “For how long should a patient undergoing HCT,
who requires ICU transfer for any reason, be treated?”
Traditionally, in centers across our country, there has been a
reluctance to offer these patients ICU care because of
signiﬁcant high mortality rates. Our results suggest that with
proper treatment, a signiﬁcant proportion of HCT patients
can be offered adequate outcomes, considering the severity
of their complications during their HCT and that in com-
parison, mortality of ICU nonimmunosuppressed patients
with severe sepsis and septic shock has been shown to be
between 20% and 40%, which is lower than the HCT popu-
lation [30,31] but similar to non-HCT neutropenic patients
with severe sepsis and septic shock [32]. Our study does not
answer the question of which patients requiring ICU
admission after allogeneic HCT should be denied that option.
Although a signiﬁcant proportion of those patients died in
the ICU, roughly 1 of 4 of the other patients survive at least
1 year after the transplantation, and our data do not allow us
to identify those patients. However, almost one half of the
patients admitted because of respiratory failure died in the
ICU compared with 1 of 3 from other causes of admission. In
this regard, in cases of other severe complications, such as
renal failure with hemodialysis requirement, which is
associated with a signiﬁcant death risk, this could induce
limitations of care, as the mortality in this scenario is almost
100% [33,34]. On the other hand, ICU transfer after autolo-
gous HCT was not associated with an increased risk of death,
so in these patients, care should not be limited upfront.
In conclusion, mortality in HCT patients admitted to the
ICU in our center is still high, especially after respiratory
failure requiring IMV. However, intensive support may be
satisfactory in about one half of patients admitted with a
prognosis in the short and medium term that is not as
unfavorable as has been previously reported, which leads us
K. Escobar et al. / Biol Blood Marrow Transplant 21 (2015) 172e195 179to offer ICU care to all HCT patients who require it during
their transplantation period.
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